Key Points
- KORU Medical Systems CTO Eric Schiller bought 5,000 shares on May 18 at an average price of $3.91, a transaction worth about $19,550. The filing means he now directly owns 5,000 shares.
- The stock was up 1.0% and opened at $4.00, near its recent trading range of $2.63 to $6.61. The company has a market cap of about $183.7 million.
- The company recently reported Q1 earnings in line with expectations, posting EPS of -$0.02 on revenue of $11.76 million. Analysts currently have a Moderate Buy consensus with an average price target of $7.25.
KORU Medical Systems, Inc. (NASDAQ:KRMD - Get Free Report) CTO Eric Schiller acquired 5,000 shares of the business's stock in a transaction on Monday, May 18th. The shares were bought at an average price of $3.91 per share, with a total value of $19,550.00. Following the completion of the transaction, the chief technology officer directly owned 5,000 shares of the company's stock, valued at approximately $19,550. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.
KORU Medical Systems Trading Up 1.0%
NASDAQ KRMD opened at $4.00 on Thursday. KORU Medical Systems, Inc. has a 1-year low of $2.63 and a 1-year high of $6.61. The company has a 50 day moving average of $4.19 and a 200-day moving average of $4.84. The company has a market cap of $183.72 million, a price-to-earnings ratio of -80.00 and a beta of 0.43.
KORU Medical Systems (NASDAQ:KRMD - Get Free Report) last posted its earnings results on Wednesday, May 6th. The company reported ($0.02) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.02). The firm had revenue of $11.76 million for the quarter, compared to analysts' expectations of $11.28 million. KORU Medical Systems had a negative net margin of 5.27% and a negative return on equity of 13.61%. On average, equities research analysts forecast that KORU Medical Systems, Inc. will post -0.04 earnings per share for the current year.
Analysts Set New Price Targets
A number of equities research analysts have issued reports on KRMD shares. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of KORU Medical Systems in a research report on Tuesday, April 21st. B. Riley Financial upped their price objective on shares of KORU Medical Systems from $7.00 to $8.00 and gave the stock a "buy" rating in a research report on Friday, March 13th. Wall Street Zen downgraded shares of KORU Medical Systems from a "buy" rating to a "hold" rating in a research report on Saturday, May 9th. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and issued a $6.00 price objective on shares of KORU Medical Systems in a research report on Friday, March 13th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, KORU Medical Systems has an average rating of "Moderate Buy" and an average price target of $7.25.
Check Out Our Latest Analysis on KORU Medical Systems
Hedge Funds Weigh In On KORU Medical Systems
Large investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets grew its holdings in KORU Medical Systems by 52.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 10,148 shares of the company's stock worth $39,000 after acquiring an additional 3,478 shares during the last quarter. Lazard Asset Management LLC bought a new stake in KORU Medical Systems in the 2nd quarter worth $59,000. Acadian Asset Management LLC bought a new stake in KORU Medical Systems in the 1st quarter worth $63,000. Arrowstreet Capital Limited Partnership bought a new stake in KORU Medical Systems in the 1st quarter worth $79,000. Finally, Invesco Ltd. bought a new stake in shares of KORU Medical Systems during the 2nd quarter valued at about $80,000. Hedge funds and other institutional investors own 58.60% of the company's stock.
About KORU Medical Systems
(
Get Free Report)
KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
